2393 results about "Cancer cell" patented technology

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The present invention relates to sonosensitive liposomes and a method for preparing the same. The sonosensitive liposomes according to the present invention improve the delivery efficiency of encapsulated drugs, and are expected to exhibit various functions in the fields of cancer treatment and drug delivery carriers by improving drug delivery effects through targeted cancer cells when used in combination with ultrasonic treatment.

The invention belongs to the field of bioinformatics, and relates to an anti-cancer drug response prediction method based on an attention mechanism. The method comprises the following steps: firstly, capturing uniform-dimension drug and cancer cell line characteristics through a multi-layer perceptron; secondly, fusing drug characteristics by adopting a Transform encoder, and constructing a cell encoder for cancer cell line characteristic polymerization; then, designing a cross-modal cross fusion module to promote information interaction between the two; and finally, predicting a semi-suppressed concentration value subjected to logarithmic transformation between the two through a multi-layer perceptron. Experimental results show that compared with an existing optimal method, the method has the advantage that the RMSE is reduced by 2.9%. According to the method, accurate prediction of the anti-cancer drug response is achieved by integrating drug and cancer cell line data, screening of potential anti-cancer drugs can be accelerated, personalized treatment schemes can be optimized, the cure rate of cancer patients is further increased, and the method has great significance in cancer treatment.

A device for modelling physiological and pathophysiological states of the brain is provided. The device comprises a hydrogel with micropattern channels having a length, width and depth. The micropattern channels comprise cells selected from the group consisting of neurons, astrocytes, microglia, oligodendrocytes, neuronal organoids, cancer cells, cancer spheroids, brain tumoral cells and combinations thereof.

The invention relates to the technical field of spectral imaging detection, in particular to a spontaneous-stimulated Raman co-localization single-cell substructure atlas analysis system and a spontaneous-stimulated Raman co-localization single-cell substructure atlas analysis method. The system comprises a femtosecond pulse excitation module used for outputting two beams of broadband femtosecond pulse laser with different frequencies and continuously adjustable optical power; the Stokes light modulation module is used for modulating the Stokes light and carrying out space beam combination on the Stokes light and the pump light; the pump light modulation module is used for modulating pump light; the spontaneous Raman laser continuous adjusting module is used for outputting spontaneous Raman laser; the stimulated Raman exciting light co-positioning module is used for combining the combined laser and the spontaneous Raman laser again, focusing the combined laser and the spontaneous Raman laser on a sample, exciting a stimulated Raman scattering signal, converting the stimulated Raman scattering signal into a digital signal and carrying out data acquisition; and the spectrum detection module is used for collecting the spontaneous Raman scattering light which is reflected and returned along the original light path, and collecting a spectrum signal to form a Raman spectrum. The method has the advantage of improving the accuracy of single-cell heterogeneity structure and cancer cell type discrimination.

The invention provides a mammary gland pathological cell image detection method and system based on an improved YOLOv7 model, and the method comprises the steps: S1, collecting mammary gland pathological section images, and generating a data set; s2, carrying out frame labeling on cells obtained in the data set; s3, segmenting the marked data set into a training set and a verification set; step S4, establishing a YOLOv7 network, and respectively adding an ASFF module and a CBAM module in three branches of the YOLOv7 network to obtain an improved YOLOv7 network; and S5, inputting the training set into the improved YOLOv7 network for training, and verifying to obtain the high-precision breast pathological section cell detection model. The improved model can effectively avoid a large semantic gap between non-adjacent levels of mammary gland cell characteristics, greatly enhance the detection capability of multi-scale cell targets such as tiny early cancer cells and large normal mammary gland tissue cells, and improve the recognition precision of early mammary gland lesion cells.

The present invention discloses a combination of different nucleic acid aptamers with 291 known targets. By performing sequencing analysis on the nucleic acid aptamer sequences of this combination through single-cell high-throughput sequencing technology, a cell atlas targeting mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be constructed. The nucleic acid aptamers covered by this combination have high specific affinity for their molecular targets. After extending adapters commercialized for sequencing platforms at both ends of the nucleic acid aptamer sequences respectively, by performing high-throughput sequencing on the nucleic acid aptamer sequences with sequencing adapters bound to the surface of mononuclear cells, high-throughput analysis of biomarkers on the surface of mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be achieved, thereby constructing a cell atlas of mononuclear cells derived from the peripheral blood of cholangiocarcinoma.

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Described herein are programmable DNA proteolytic target chimera complexes that can be used both for the direct treatment of cancer by inhibiting biochemical pathways that are overexpressed in cancer cells, and for the indirect treatment of cancer by recruiting the E3 ligase complex to engage with a protein of interest or a mutant thereof and initiating proteolysis. Also described herein are methods of using the complexes in the treatment of cancer, as well as compositions comprising the complexes.

The invention provides a screening method and application of an early prediction marker of papillary thyroid cancer, the early prediction marker of papillary thyroid cancer is P4HA2, application of a reagent for detecting the expression level of P4HA2 in preparation of a product is provided, and a P4HA2 inhibitor including a substance for knocking down P4HA2 gene expression is also provided. The invention also provides application of the P4HA2 inhibitor in preparation of a product for inhibiting migration and / or proliferation of thyroid cancer cells, and a screening method of a biomarker for predicting papillary thyroid cancer. The marker can be used for prediction and early prediction of papillary thyroid cancer, knock-down of the marker can also be used for prediction and early prediction of papillary thyroid cancer, early screening can be better completed, benign and malignant nodules are helped to be distinguished, unnecessary invasive detection is reduced, and the detection efficiency is improved. And a new view angle is provided for molecular mechanism research and early diagnosis of thyroid cancer.

An example method includes identifying an image of a tissue sample obtained from a subject. The tissue sample includes at least one cancer cell and at least one non-cancer cell. The example method further includes identifying the at least one non-cancer cell depicted in the image; generating a metric based on the at least one non-cancer cell depicted in the image; and predicting, based on the metric, whether the at least one cancer cell is susceptible to at least one treatment.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

Provided herein are exosomes (such as modified exosomes) that include or express one or more surface proteins that are covalently linked to an immunomodulatory molecule or a therapeutic molecule. In particular examples, the exosomes are from a cancer cell, a stem cell, or an immune cell. Also provided are methods of making and using the modified exosomes, for example for treating cancer.

The invention relates to the technical field of biological medicine, and discloses an aromatic polyketone compound as well as a preparation method and application thereof. According to the aromatic polyketone compound, a compound I and a compound II are separated from an ethyl acetate extract of rice fermentation liquor of Crystalomyces hyricus, and the compound I and the compound II are respectively named as Crystaloketide A and Crystalomycin D. In-vitro anti-cancer activity tests are carried out on the Crystaloketide A and the Crystalomycin D. According to the aromatic polyketone compound disclosed by the invention, the anti-cancer activity of the Crystaloketide A and the Crystalomycin D. Results show that the compound I and the compound II have the effects of inhibiting human cervical cancer cells, human liver cancer cells, human nerve cancer cells and human pancreatic cancer cells respectively, so that the compound I and the compound II can be further prompted to be used for preparing anti-cancer drugs.

By producing the proper wave interference using superimposed angularly separate waves that overlap with the proper time-phase relationship (called “Time-Correlated Standing-wave Interference”), wave energy is amplified (by “Coherent Intensity Amplification”) and teleported to precise locations. For instance, in one application, energy is teleported to one or more areas within a living body for such therapeutic applications as destroying cancer cells or plaques within arteries. A system implementing this technique creates amplified constructive interference at one or more selected disease locations, while producing destructive interference at surrounding locations. In this application example, the technique allows energy to be “teleported” to tumor cells, plaques, or other diseased cells, for instance, to destroy them, while surrounding healthy cells receive virtually no energy, obviating collateral damage from the treatment. The same method can be used to diagnose disease by detecting energy teleported to different locations.

An antigen peptide is provided specifically for treating individuals suffering from ovarian cancer, preferably based on BRCA1 gene c. 5470_5477del8 mutation. It is selected from amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 6, or derived by substitution, deletion and / or addition of at least one amino acid. The neoantigen polypeptides of the present disclosure can significantly activate T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro, stimulating the release of the cytokine IFN-y, indicating notable immunogenicity. This enhances T lymphocytes' ability to target and kill cancer cells from ovarian cancer patients carrying the BRCA1 gene c. 5470_5477del8 mutation. Additionally, the antigen peptide can activate and expand human T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro for adoptive cell therapy. The antigen peptide of the present disclosure addresses the gap in personalized antigen peptide therapies for ovarian cancer patients with BRCAl-c. 5470_5477del8 somatic mutations.

The invention discloses a dual-channel fusion cancer drug response prediction method, and belongs to the technical field of biological information. The method aims at solving the problems that an existing prediction method is only limited to intra-modal feature extraction, and a complex nonlinear cooperative relation between a drug and cancer cells is difficult to capture. Multi-omics data, drug molecular structure information and cancer cell line drug reaction data are integrated from databases such as CCLE, GDSC and PubChem, and unified input features are formed through standardization and feature construction. Introducing a hierarchical double-attention conversion network into the first channel to carry out characterization learning on the multi-modal features of the drug and the cell line, and constructing a high-order attention neighbor interaction graph convolutional network in the second channel to capture graph structure information of cancer drug response. And carrying out adaptive weighting on output results of the two channels by using a PPO-based fusion module so as to realize a dynamic optimal decision. And finally, generating a drug sensitivity prediction result of the cancer cell line through a classification predictor.

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.

According to the endometrial cancer cell detection method and system provided by the embodiment of the invention, firstly, an image block is paired with a pathological report text, and unified semantic features are obtained by utilizing multi-positive sample comparison learning; performing semantic entropy-driven dynamic shielding-random shuffling self-supervision training on the visual neural network; secondly, after cell nucleuses are positioned, a weighted cell graph is constructed with cells as nodes and proximity relations as edges, topological features are obtained, and then the topological features, visual features and semantic features are subjected to cross-scale attention and gating fusion to generate multi-modal features; a detection head jointly outputs a category, a frame and a mask, and comprehensive cross-modal consistency loss is subjected to supervision or weak supervision training; and a'cancer-normal 'preference pair is automatically generated by further utilizing high and low probability regions output by the initial model, a reward model is trained, and a PPO strategy is adopted for iterative fine tuning, so that cell-level cancer focus detection can be accurately and robustly completed without a large number of pixel-level labels, and the pathological screening efficiency and accuracy are remarkably improved.

The invention belongs to the technical field of medicines, and provides a novel method for overcoming multidrug resistance of tumors based on innate immune regulation. The invention relates to an application of an agonist of an innate immune STING pathway and an ENPP1 inhibitor in overcoming multidrug resistance of tumors and enhancing an anti-tumor curative effect. The STING agonist or the ENPP1 inhibitor is combined with an anti-tumor chemical drug for application, so that the effects of overcoming the multi-drug resistance of chemotherapeutic drugs and enhancing the anti-tumor curative effect are achieved. The STING agonist / or ENPP1 inhibitor has the effect of reversing multidrug resistance of tumors, and can enhance the sensitivity of cancer cells to chemotherapeutic drugs and monoclonal antibody drugs, so that the curative effect of antitumor drugs is enhanced, and the STING agonist / or ENPP1 inhibitor is expected to be developed into a novel reversal agent drug for multidrug resistance tumors. The novel anti-multidrug resistance strategy provides a new thought for drug design and cancer treatment, and has a great application prospect in clinical treatment of cancers.

[Problem] To provide a novel ferroptosis-inducing drug, and in particular, to provide a ferroptosis induction promoter that can effectively promote the induction of ferroptosis even in a cell having ferroptosis resistance even in a ferroptosis-inducing environment (for example, cancer cells and senescent cells). [Solution] Provided is a ferroptosis induction promoter comprising a drug that can reduce lysosomal pH.

The invention discloses a compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a compound which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The compound provided by the invention provides a new scheme for treating lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The invention discloses an organelle-targeted fluorescent probe for specific detection of tumor cells as well as preparation and application of the organelle-targeted fluorescent probe, and the specific structural formula of the fluorescent probe is as follows: BCY-DP shows obvious specific targeting ability of tumor cell mitochondria and has been applied to ONOO-selective imaging in living cell mitochondria; results show that the BCY-DP has high selectivity on ONOO <-> in tumor cells, can successfully distinguish the ovarian cancer cells from normal ovarian cells, and can be used for diagnosis of cancer cells.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention discloses a preparation method and application of roasted barley and malt polysaccharide with an anti-cancer effect. The roasted barley malt polysaccharide is a neutral heteropolysaccharide which mainly takes-> 3)-beta-D-Glcp-(1-> and->-beta-D-Glcp-(1->) as main chains, branches exist at O-3 / O-4 positions, and the branch chains are mainly composed of-> 4)-beta-D-Xylp-(1->,-> 3, 4)-beta-D-Xylp-(1-> and alpha-D-Glcp-(1->. The monosaccharide composition comprises arabinose, glucose and xylose in a molar mass ratio of 1.86: 33.43: 1.00, and the molecular weight is 23.81 kDa. In-vitro activity experiments prove that the roasted barley malt polysaccharide disclosed by the invention has a remarkable inhibition effect on proliferation of liver cancer cells, lung cancer cells, breast cancer cells and colorectal cancer cells, particularly on the liver cancer cells, and shows outstanding anti-tumor activity, so that the roasted barley malt polysaccharide is expected to be developed and applied in the fields of foods, health-care products or medicines.

The present invention addresses the problem of producing a novel anti-CDH3 humanized antibody and providing, by using the antibody, an (anti-CDH3 humanized antibody)-drug conjugate capable of more efficiently killing CDH3-expressing cancer cells. According to the present invention, either of the following antibodies is provided. (1) An anti-CDH3 humanized antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 2; or (2) an anti-CDH3 humanized antibody having a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4.

The present invention provides a chimeric antigen receptor (CAR) that recognizes CSPG4 as well as methods of use in the treatment of diseases and disorders.

The invention discloses a paris polyphylla extract which is prepared by the following steps: extracting crushed paris polyphylla for 1-3 times by adopting a cyclodextrin solution at 30-70 DEG C under ultrasonic waves, collecting and combining an extracting solution, separating and purifying the extracting solution through macroporous resin, eluting the extracting solution through an ethanol solution with the volume concentration of 70%, and concentrating and drying the eluent, thereby obtaining the paris polyphylla extract. The paris polyphylla extract is applied to treatment of bladder cancer, experimental results show that the paris polyphylla extract has an obvious inhibiting effect on proliferation of human bladder cancer cells T24 and UM-UC-3, a theoretical basis is provided for deep research on the anti-tumor action mechanism of paris polyphylla, and the paris polyphylla extract is of great significance in revealing research on anti-tumor effective active ingredients of paris polyphylla and has a wide application prospect. The invention provides a new way and means for treating tumors.